RESUMO
In vitro-in vivo extrapolation (IVIVE) linked with physiologically based pharmacokinetics (PBPK) modeling is used to predict the fates of drugs in patients. Ideally, the IVIVE-PBPK models should incorporate systems information accounting for characteristics of the specific target population. There is a paucity of such scaling factors in cancer, particularly microsomal protein per gram of liver (MPPGL) and cytosolic protein per gram of liver (CPPGL). In this study, cancerous and histologically normal liver tissue from 16 patients with colorectal liver metastasis were fractionated to microsomes and cytosol. Protein content was measured in homogenates, microsomes, and cytosol. The loss of microsomal protein during fractionation was accounted for using corrections based on NADPH cytochrome P450 reductase activity in different matrices. MPPGL was significantly lower in cancerous tissue (24.8 ± 9.8 mg/g) than histologically normal tissue (39.0 ± 13.8 mg/g). CPPGL in cancerous tissue was 42.1 ± 12.9 mg/g compared with 56.2 ± 16.9 mg/g in normal tissue. No correlations between demographics (sex, age, and body mass index) and MPPGL or CPPGL were apparent in the data. The generated scaling factors together with assumptions regarding the relative volumes of cancerous versus noncancerous tissue were used to simulate plasma exposure of drugs with different extraction ratios. The PBPK simulations revealed a substantial difference in drug exposure (area under the curve), up to 3.3-fold, when using typical scaling factors (healthy population) instead of disease-related parameters in cancer population. These indicate the importance of using population-specific scalars in IVIVE-PBPK for different disease states. SIGNIFICANCE STATEMENT: Accuracy in predicting the fate of drugs from in vitro data using IVIVE-PBPK depends on using correct scaling factors. The values for two of such scalars, namely microsomal and cytosolic protein per gram of liver, is not known in patients with cancer. This study presents, for the first time, scaling factors from cancerous and matched histologically normal livers. PBPK simulations of various metabolically cleared drugs demonstrate the necessity of population-specific scaling for model-informed precision dosing in oncology.
Assuntos
Antinematódeos/farmacocinética , Neoplasias Colorretais/patologia , Neoplasias Hepáticas/fisiopatologia , Fígado/metabolismo , Modelos Biológicos , Adulto , Idoso , Idoso de 80 Anos ou mais , Antinematódeos/administração & dosagem , Neoplasias Colorretais/tratamento farmacológico , Relação Dose-Resposta a Droga , Feminino , Hepatectomia , Eliminação Hepatobiliar , Humanos , Fígado/patologia , Fígado/cirurgia , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Masculino , Taxa de Depuração Metabólica , Microssomos Hepáticos/metabolismo , Pessoa de Meia-IdadeRESUMO
Soil-transmitted helminths (Ascaris lumbricoides, hookworm and Trichuris trichiura) infect about one-fifth of the world's population. The currently available drugs are all highly efficacious against A. lumbricoides. However, they are only moderately efficacious against hookworm and poorly efficacious against T. trichiura. Oxantel, a tetrahydropyrimidine derivative discovered in the 1970s, has recently been brought back to our attention given its high efficacy against T. trichiura infections (estimated 76% cure rate and 85% egg reduction rate at a 20 mg/kg dose). This review summarizes the current knowledge on oxantel pamoate and its use against T. trichiura infections in humans. Oxantel pamoate acts locally in the human gastrointestinal tract and binds to the parasite's nicotinic acetylcholine receptor (nAChR), leading to a spastic paralysis of the worm and subsequent expulsion. The drug is metabolically stable, shows low permeability and low systemic bioavailability after oral use. Oxantel pamoate was found to be safe in humans, with only a few mild adverse events reported. Several clinical trials have investigated the efficacy of this drug against T. trichiura and suggest that oxantel pamoate is more efficacious against T. trichiura than the currently recommended drugs, which makes it a strong asset to the depleted drug armamentarium and could help delay or even prevent the development of resistance to existing drugs. We highlight existing data to support the use of oxantel pamoate against T. trichiura infections.
Assuntos
Antinematódeos/farmacologia , Antinematódeos/uso terapêutico , Infecções por Uncinaria/tratamento farmacológico , Pamoato de Pirantel/análogos & derivados , Animais , Antinematódeos/efeitos adversos , Antinematódeos/farmacocinética , Relação Dose-Resposta a Droga , Interações Medicamentosas , Humanos , Pamoato de Pirantel/efeitos adversos , Pamoato de Pirantel/farmacocinética , Pamoato de Pirantel/farmacologia , Pamoato de Pirantel/uso terapêutico , TrichurisRESUMO
The pharmacokinetics of levamisole were determined in the belugas after single intravascular (IV), and single and multiple-dose oral by feed administrations. Also, the effect of levamisole (LVM) on the stress and immune responses of belugas were assessed. One hundred-fourteen healthy belugas in 4 different groups received single LVM administration at the doses of 50 and 100 mg/kg via IV and oral routes. A separate group of 24 belugas were administered oral LVM at the dose of 100 mg/kg for 5 days. Blood samples were collected at different time points after administrations to measure plasma concentrations of LVM by a validated high-performance liquid chromatography (HPLC) assay. For immunological evaluations, a total of 126 belugas received 50 and 100 mg/kg LVM via medicated feed for 5 days or served as the control without any medication; blood samples were recovered on day 0, 1, 3, 5, 7, 10, and 14 to measure hemolytic activity of the complement system (HAC50), serum lysozyme activity, serum antibacterial activity, glucose, cortisol, total protein, albumin and C3 contents. In the single-dose administration, quantified LVM concentrations were dose-dependent and the oral bioavailability was in the range of 43.2-49.6%. In the multiple-dose administration, the peak plasma concentration at the steady state was 45.2 mg/ml, and accumulation ratio was calculated as 3.6. In the immunological study, LVM especially at the dose of 100 mg/kg increased HAC50, lysozyme and antibacterial activity in the sera of treated fish. No significant effect of LVM on glucose and albumin content was observed, but cortisol levels decreased and C3 content was increased, more significantly by LVM at the dose of 100 mg/kg. Our results indicate that LVM is well absorbed after oral administration and reached to concentrations that can affect stress indicators and improve immune responses in belugas.
Assuntos
Antinematódeos/farmacocinética , Peixes/sangue , Levamisol/farmacocinética , Animais , Antinematódeos/administração & dosagem , Antinematódeos/sangue , Área Sob a Curva , Esquema de Medicação , Peixes/imunologia , Peixes/metabolismo , Meia-Vida , Levamisol/administração & dosagem , Levamisol/sangueRESUMO
Therapeutic advances for osteosarcoma have stagnated over the past several decades, leading to an unmet clinical need for patients. The purpose of this study was to develop a novel therapy for osteosarcoma by reformulating and validating niclosamide, an established anthelminthic agent, as a niclosamide stearate prodrug therapeutic (NSPT). We sought to improve the low and inefficient clinical bioavailability of oral dosing, especially for the relatively hydrophobic classes of anticancer drugs. Nanoparticles were fabricated by rapid solvent shifting and verified using dynamic light scattering and UV-vis spectrophotometry. NSPT efficacy was then studied in vitro for cell viability, cell proliferation, and intracellular signaling by Western blot analysis; ex vivo pulmonary metastatic assay model; and in vivo pharmacokinetic and lung mouse metastatic model of osteosarcoma. NSPT formulation stabilizes niclosamide stearate against hydrolysis and delays enzymolysis; increases circulation in vivo with t 1/2 approximately 5 hours; reduces cell viability and cell proliferation in human and canine osteosarcoma cells in vitro at 0.2-2 µmol/L IC50; inhibits recognized growth pathways and induces apoptosis at 20 µmol/L; eliminates metastatic lesions in the ex vivo lung metastatic model; and when injected intravenously at 50 mg/kg weekly, it prevents metastatic spread in the lungs in a mouse model of osteosarcoma over 30 days. In conclusion, niclosamide was optimized for preclinical drug delivery as a unique prodrug nanoparticle injected intravenously at 50 mg/kg (1.9 mmol/L). This increased bioavailability of niclosamide in the blood stream prevented metastatic disease in the mouse. This chemotherapeutic strategy is now ready for canine trials, and if successful, will be targeted for human trials in patients with osteosarcoma.
Assuntos
Antineoplásicos/farmacologia , Neoplasias Ósseas/tratamento farmacológico , Niclosamida/farmacologia , Osteossarcoma/tratamento farmacológico , Pró-Fármacos/farmacologia , Estearatos/farmacologia , Animais , Antinematódeos/química , Antinematódeos/farmacocinética , Antinematódeos/farmacologia , Antineoplásicos/química , Antineoplásicos/farmacocinética , Apoptose , Neoplasias Ósseas/metabolismo , Neoplasias Ósseas/patologia , Proliferação de Células , Cães , Avaliação Pré-Clínica de Medicamentos , Reposicionamento de Medicamentos , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Niclosamida/química , Niclosamida/farmacocinética , Osteossarcoma/metabolismo , Osteossarcoma/patologia , Pró-Fármacos/química , Pró-Fármacos/farmacocinética , Estearatos/química , Estearatos/farmacocinética , Distribuição Tecidual , Células Tumorais Cultivadas , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
In a context of nematodicidal resistance, anthelmintic combinations have emerged as a reliable pharmacological strategy to control gastrointestinal nematodes in grazing systems of livestock production. The current work evaluated the potential drug-drug interactions following the coadministration of two macrocyclic lactones (ML) ivermectin (IVM) and abamectin (ABM) to parasitized cattle using a pharmacokinetic/pharmacodynamic (PK/PD) approach. The kinetic behavior of both compounds administered either separately or coadministered was assessed and the therapeutic response of the combination was evaluated under different resistance scenarios. In the pharmacological trial, calves received a single subcutaneous (s.c.) injection of IVM (100⯵g/Kg); a single s.c. injection of ABM (100⯵g/Kg) or IVMâ¯+â¯ABM (50⯵g/Kg each) administered in different injection sites to reach a final ML dose of 100⯵g/Kg (Farm 1). Plasma samples were taken from those animals up to 20 days post-treatment. IVM and ABM plasma concentrations were quantified by HPLC. A parasitological trial was carried out in three farms with different status of nematodes resistance to IVM. Experimental animals received IVM (200⯵g/Kg), ABM (200⯵g/Kg) or IVMâ¯+â¯ABM (100⯵g/Kg each) in Farm 2, and IVMâ¯+â¯ABM (200⯵g/Kg each) in Farms 3 and 4. The anthelmintic efficacy was determined by fecal egg count reduction test (FECRT). PK analysis showed similar trends for IVM kinetic behavior after coadministration with ABM. Conversely, the ABM elimination half-life was prolonged and the systemic exposure during the elimination phase was increased in the presence of IVM. Although IVM alone failed to control Cooperia spp., the combination IVMâ¯+â¯ABM was the only treatment that achieved an efficacy higher than 95% against resistant Cooperia spp. in all farms. In fact, when Cooperia spp. was the main genus within the nematode population and Haemonchus spp. was susceptible or slightly resistant to ML (Farms 2 and 4), the total FECR for the combination IVMâ¯+â¯ABM was higher than 90%. Instead, when the predominant nematode genus was a highly resistant Haemonchus spp. (Farm 3), the total FECR after the combined treatment was as low as the single treatments. Therefore, the rational use of these pharmacological tools should be mainly based on the knowledge of the epidemiology and the nematode susceptibility status in each cattle farm.
Assuntos
Antinematódeos/farmacologia , Doenças dos Bovinos/tratamento farmacológico , Haemonchus/efeitos dos fármacos , Ivermectina/análogos & derivados , Ivermectina/farmacologia , Rabditídios/efeitos dos fármacos , Animais , Antinematódeos/farmacocinética , Bovinos , Interações Medicamentosas , Hemoncose/tratamento farmacológico , Hemoncose/veterinária , Ivermectina/farmacocinética , Masculino , Distribuição Aleatória , Infecções por Rhabditida/tratamento farmacológico , Infecções por Rhabditida/veterináriaRESUMO
The pharmacokinetics and bioavailability of levamisole were determined in red-eared slider turtles after single intravenous (IV), intramuscular (IM), and subcutaneous (SC) administration. Nine turtles received levamisole (10 mg/kg) by each route in a three-way crossover design with a washout period of 30 days. Blood samples were collected at time 0 (pretreatment), and at 0.25, 0.5, 1, 1.5, 3, 6, 9, 12, 18, 24, 36, and 48 hr after drug administration. Plasma levamisole concentrations were determined by a high-performance liquid chromatography assay. Data were analyzed by noncompartmental methods. The mean elimination half-life was 5.00, 7.88, and 9.43 hr for IV, IM, and SC routes, respectively. The total clearance and volume of distribution at steady state for the IV route were 0.14 L hr-1 kg-1 and 0.81 L/kg, respectively. For the IM and SC routes, the peak plasma concentration was 9.63 and 10.51 µg/ml, respectively, with 0.5 hr of Tmax . The bioavailability was 93.03 and 115.25% for the IM and SC routes, respectively. The IM and SC route of levamisole, which showed the high bioavailability and long t1/2Êz , can be recommended as an effective way for treating nematodes in turtles.
Assuntos
Antinematódeos/farmacocinética , Levamisol/farmacocinética , Tartarugas/sangue , Animais , Antinematódeos/sangue , Área Sob a Curva , Disponibilidade Biológica , Estudos Cross-Over , Meia-Vida , Injeções Intramusculares , Injeções Intravenosas , Injeções Subcutâneas , Levamisol/sangueRESUMO
BACKGROUND: Poorly water-soluble and photosensitive pesticide compounds are difficult to be formulated as environmentally friendly formulations with high efficacy. Conventional wettable powder, emulsifiable concentrate and emulsion in water have disadvantages of dust drift, overuse of organic solvent and low efficacy. Therefore, there is an urgent need to construct a novel formulation to improve the bioavailability of pesticides. RESULTS: An abamectin nanosuspension was developed using a wet-milling method combined with orthogonal experimental design. The average particle sizes of the abamectin nanosuspension measured by dynamic light scattering, scanning electron microscope and transmission electron microscope were 233, 90 and 140 nm, respectively. The zeta potential and sliding angle on cabbage leaves were -36.9 mV and 62°. Retention and anti-photolysis were around 1.5 and 1.6 times those of emulsions in water. Furthermore, the biological activity of the nanosuspension towards diamondback moths was approximately twice that of conventional formulations. CONCLUSION: This study provides an easy and scalable technique for constructing pesticide nanosuspensions. The preparation and composition of the nanosuspension avoid the use of organic solvents. Application of the highly effective nanoformulation will significantly enhance pesticide efficacy, and reduce the dosage and environmental pollution of the pesticide. © 2019 Society of Chemical Industry.
Assuntos
Acaricidas/farmacocinética , Antinematódeos/farmacocinética , Inseticidas/farmacocinética , Ivermectina/análogos & derivados , Nanopartículas/química , Disponibilidade Biológica , Ivermectina/farmacocinética , Tamanho da Partícula , Solubilidade , MolhabilidadeRESUMO
Ascaris suum is a widespread parasitic nematode that causes infection in pigs with high prevalence rates. Oxfendazole (OFZ) is effective against A. suum when used at a single high oral dose of 30â¯mg/kg. The aim of this study was to assess the pattern of distribution/accumulation of OFZ and its metabolites, in bloodstream (plasma), mucosal tissue and contents from small and large intestine and adult specimens of A. suum collected from infected and treated pigs. The activity of glutathione-S-transferases (GSTs) in A. suum was also investigated. Infected pigs were orally treated with OFZ (30â¯mg/kg) and sacrificed at 0, 3, 6 and 12â¯h after treatment. Samples of blood, mucosa and contents from both small and large intestine as well as adult worms were obtained and processed for quantification of OFZ/metabolites by HPLC. OFZ was the main analyte measured in all of the evaluated matrixes. The highest drug concentrations were determined in small (AUC0-t 718.7⯱â¯283.5⯵gâ¯h/g) and large (399.6⯱â¯110.5⯵gâ¯h/g) intestinal content. Concentrations ranging from 1.35 to 2.60⯵g/g (OFZ) were measured in adult A. suum. GSTs activity was higher after exposure to OFZ both in vivo and ex vivo. The data obtained here suggest that the pattern of OFZ accumulation in A. suum would be more related to the concentration achieved in the fluid and mucosa of the small intestine than in other tissues/fluids. It is expected that increments in the amount of drug attained in the tissues/fluids of parasite location will correlate with increased drug concentration within the target parasite, and therefore with the resultant treatment efficacy. The results are particularly relevant considering the potential of OFZ to be used for soil transmitted helminths (STH) control programs and the advantages of pigs as a model to assess drug treatment to be implemented in humans.
Assuntos
Antinematódeos/farmacocinética , Ascaríase/tratamento farmacológico , Ascaris suum/metabolismo , Benzimidazóis/farmacocinética , Animais , Antinematódeos/uso terapêutico , Área Sob a Curva , Ascaríase/metabolismo , Ascaríase/parasitologia , Benzimidazóis/uso terapêutico , Cromatografia Líquida de Alta Pressão , Citosol/enzimologia , Dinitroclorobenzeno/metabolismo , Fezes/parasitologia , Feminino , Fenbendazol/análise , Glutationa Transferase/metabolismo , Mucosa Intestinal/metabolismo , Mucosa Intestinal/parasitologia , Intestino Grosso/metabolismo , Intestino Delgado/metabolismo , Contagem de Ovos de Parasitas , Espectrofotometria , SuínosRESUMO
BACKGROUND: Flubendazole, originally developed to treat infections with intestinal nematodes, has been shown to be efficacious in animal models of filarial infections. For treatment of filarial nematodes, systemic exposure is needed. For this purpose, an orally bioavailable amorphous solid dispersion (ASD) formulation of flubendazole was developed. As this formulation results in improved systemic absorption, the pharmacokinetic and toxicological profile of the flubendazole ASD formulation have been assessed to ensure human safety before clinical trials could be initiated. METHODS & FINDINGS: Safety pharmacology, toxicity and genotoxicity studies have been conducted with the flubendazole ASD formulation. In animals, flubendazole has good oral bioavailability from an ASD formulation ranging from 15% in dogs, 27% in rats to more than 100% in jirds. In in vivo toxicity studies with the ASD formulation, high systemic exposure to flubendazole and its main metabolites was reached. Flubendazole, up to high peak plasma concentrations, does not induce Cmax related effects in CNS or cardiovascular system. In repeated dose toxicity studies in rats and dogs, flubendazole-induced changes were observed in haematological, lymphoid and gastrointestinal systems and in testes. In dogs, the liver was an additional target organ. Upon treatment cessation, at least partial recovery was observed for these changes in dogs. In rats, the No Observed Adverse Effect Level (NOAEL) was 5 mg (as base)/kg body weight/day (mg eq./kg/day) in males and 2.5 mg eq./kg/day in females. In dogs, the NOAEL was lower than 20 mg eq./kg/day. Regarding genotoxicity, flubendazole was negative in the Ames test, but positive in the in vivo micronucleus test. CONCLUSIONS: Based on these results, in combination with previously described genotoxicity and reproductive toxicity data and the outcome of the preclinical efficacy studies, it was concluded that no flubendazole treatment regimen can be selected that would provide efficacy in humans at safe exposure.
Assuntos
Antinematódeos/efeitos adversos , Antinematódeos/farmacocinética , Mebendazol/análogos & derivados , Testes de Mutagenicidade , Administração Oral , Animais , Antinematódeos/administração & dosagem , Cães , Avaliação Pré-Clínica de Medicamentos , Feminino , Gerbillinae , Masculino , Mebendazol/administração & dosagem , Mebendazol/efeitos adversos , Mebendazol/farmacocinética , Ratos Sprague-DawleyRESUMO
Potential effects on cardiac repolarization of single doses of moxidectin, a potent long-acting macrocyclic lactone endectocide, were assessed in a concentration-QT (c-QT; exposure-response) study. This double-blind, placebo-controlled, parallel-group study in healthy male volunteers (n = 60) randomized subjects to a single oral dose of moxidectin (4 mg, 8 mg, 16 mg, 24 mg, or 36 mg) or matching placebo. Serial plasma samples for pharmacokinetic (PK) analysis and concurrent triplicate electrocardiogram measurements were taken at baseline and 14 prespecified time points over 72 hours, yielding 900 QT interval-plasma concentration time-matched pairs. Moxidectin had no statistically significant or clinically relevant impact on QT interval at any dose level. The primary mixed effects model analysis revealed no treatment-related impact on the Fridericia-corrected QT interval-plasma concentration gradient (-0.0077, 90% confidence interval (CI) -0.0255 to +0.0101).
Assuntos
Antinematódeos/efeitos adversos , Cardiotoxicidade/diagnóstico , Macrolídeos/efeitos adversos , Adulto , Antinematódeos/administração & dosagem , Antinematódeos/farmacocinética , Cardiotoxicidade/etiologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Eletrocardiografia/efeitos dos fármacos , Meia-Vida , Voluntários Saudáveis , Frequência Cardíaca/efeitos dos fármacos , Humanos , Macrolídeos/administração & dosagem , Macrolídeos/farmacocinética , Masculino , Pessoa de Meia-Idade , Doenças Negligenciadas/tratamento farmacológico , Oncocercose/tratamento farmacológico , Adulto JovemRESUMO
The objective of this study was to investigate the effect of dispersion states of azone in gels on the transdermal permeation of levamisole hydrochloride (LH). LH hydroalcoholic gels containing azone of different dispersion states were prepared by varying the contents of azone and Tween 80, and the in vitro transdermal permeation of LH across excised rat skin was evaluated. Depending on the content of azone, mixed solvents, and solubilizer used, azone presented as dissolved molecules, solubilized in micelles, and fine or coarse emulsion droplets in gels. Dramatically increased transdermal permeation of LH within the azone contents between 0.25% and 0.75% indicated high transdermal enhancement efficiency of the molecular or micellar azone, and extra azone that existed as oil droplets did not fully exert transdermal penetration enhancement of LH. Although solubilizer (Tween 80) can greatly increase the solubility of azone, only small amount of Tween 80 (0.5%) in the gel significantly increased the steady-state flux of LH. Addition of extra amount of Tween 80 (>0.5%) reduced the amount of azone distributed in the skin, and thus decreased the transdermal drug permeation. The results partly elucidated the versatile effects of the dispersion states of azone on the transdermal permeation of hydrophilic drug from semisolid gels.
Assuntos
Antinematódeos/farmacocinética , Antirreumáticos/farmacocinética , Azepinas/química , Hidrogéis/química , Levamisol/farmacocinética , Absorção Cutânea/efeitos dos fármacos , Administração Cutânea , Animais , Antinematódeos/administração & dosagem , Antirreumáticos/administração & dosagem , Azepinas/farmacologia , Hidrogéis/farmacologia , Levamisol/administração & dosagem , Masculino , Micelas , Permeabilidade/efeitos dos fármacos , Ratos Sprague-Dawley , Pele/efeitos dos fármacos , Pele/metabolismo , SolubilidadeRESUMO
The objective of this study was to prepare a new compound fenbendazole tablet containing 29.7 % fenbendazole, 1.50 % praziquantel and 0.059 % ivermectin for oral administration. The tablets were successfully prepared using mannitol as filler agent, polyvinyl polypyrrolidone as disintegrant, 5 % povidone (PVAK30) as a binder agent and magnesium stearate as lubricant. The appearance, hardness, fragility, time limit of disintegration and fenbendazole dissolution at 45 min all met the technical standards of the Ministry of Agriculture for the People's Republic of China. We used high performance liquid chromatography and electrospray-mass spectrometry for drug detection. Oral administration of 100 mg/kg fenbendazole, 5 mg/kg praziquantel and 0.2 mg/kg ivermectin using a non-compartmental model defined peak plasma concentrations (Cmax) of 495, 826, 73 ng/mL, and 218 ng/mL for the metabolite oxfendazole, respectively. The area under the curve (AUClast) values for these drugs were 4653, 1045, 1971 and 5525 h×ng/mL, respectively. This study enriches the pharmacokinetic data of compound fenbendazole tablets using dogs as a model system. The new tablet formulation was assimilated quickly and systemically and this study will be beneficial for the clinical application of parasite treatments in dogs.
Assuntos
Antinematódeos/administração & dosagem , Antinematódeos/farmacocinética , Fenbendazol/administração & dosagem , Fenbendazol/farmacocinética , Administração Oral , Animais , Cromatografia Líquida de Alta Pressão , Cães , Composição de Medicamentos , Excipientes , Meia-Vida , Manitol , Povidona , Reprodutibilidade dos Testes , Espectrometria de Massas por Ionização por Electrospray , Ácidos Esteáricos , ComprimidosRESUMO
The novel pyrazoline derivative, BHX, has recently been shown to exhibit potent anti-tumour activity by blocking the Wnt/ß-catenin signalling pathway. However, its effect on breast cancer growth and invasion are unknown. Our results show that BHX suppresses MDA-MB-231 cell viability and colony formation in a dose-dependent manner, and induces apoptosis and G0/G1 phase arrest. BHX-treated breast cancer cells showed morphological characteristics of cells undergoing apoptosis. Furthermore, BHX inhibited cell migration and invasion, which was associated with increased E-cadherin mRNA and protein expression, and down-regulation of SNAIL and vimentin. In addition, BHX induced the generation of intracellular ROS and decreased ß-catenin protein and mRNA expression. We used a mouse xenograft model to investigate the effects of BHX in vivo, where the growth of MDA-MB-231 xenografted tumours was suppressed in nude mice treated continuously with BHX for 21 days. Finally, the rat plasma concentration of BHX was measured by ultra-performance liquid-chromatography tandem mass spectrometry and the pharmacokinetic parameters of BHX were processed by non-compartmental analysis. In conclusion, BHX merits further study as a novel therapeutic small molecule for the treatment of breast cancer.
Assuntos
Antinematódeos/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Regulação para Baixo , Pirazóis/administração & dosagem , Via de Sinalização Wnt/efeitos dos fármacos , Animais , Antinematódeos/farmacocinética , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Transição Epitelial-Mesenquimal/efeitos dos fármacos , Feminino , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Camundongos , Camundongos Nus , Invasividade Neoplásica , Pirazóis/farmacocinética , Ratos , Resultado do Tratamento , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
BACKGROUND: The anthelmintic efficacy of the 0.5% w/v topical formulation of eprinomectin (EPN), EPRINEX® Pour-on (Merial) when administered at 1 mg/kg body weight was evaluated in sheep in two dose confirmation laboratory studies and one multicenter field study. In addition, the pharmacokinetics of EPN when administered at that dosage to adult sheep was determined. RESULTS: In the two dose confirmation studies, which included 10 sheep each, sheep treated with topical EPN had significantly (p < 0.05) fewer of the following nematodes than the untreated sheep with overall reduction of nematode counts by >99%: adult Dictyocaulus filaria, Haemonchus contortus, Teladorsagia circumcincta(pinnata/trifurcata), Trichostrongylus axei, T. colubriformis, T. vitrinus, Cooperia curticei, Nematodirus battus, Strongyloides papillosus, Chabertia ovina and Oesophagostomum venulosum, and inhibited fourth-stage Teladorsagia larvae. A total of 196 sheep harboring naturally acquired gastrointestinal nematode infections were included in the field efficacy study at two sites each in Germany (48 Merino x Ile de France lambs, 52 adult Merino females) and in Italy (adult male and female Bagnolese, Lacaune, Lacaune x Bagnolese, Bagnolese x Sarda sheep; 48 animals per site). Animals were blocked on pre-treatment body weight and within each block, one animal was randomly assigned to the control (untreated) group and three animals were randomly assigned to be treated with topical EPN. Examination of feces 14 days after treatment demonstrated that, relative to the controls, topical EPN-treated sheep had significantly (p < 0.0001) lower strongylid egg counts. Reduction was ≥97% at each site and 98.6% across all sites. Pharmacokinetics of EPN following single treatment with topical EPN were determined in eight ~4.5 year old female Merino cross sheep based on the analysis of plasma samples which were collected from two hours to 21 days following treatment. The main pharmacokinetic parameters were: Cmax 6.20 ± 1.71 ng/mL, AUClast 48.8 ± 19.2 day*ng/mL, Tmax 3.13 ± 2.99 days and T1/2 6.40 ± 2.95 days. No treatment-related health problems or adverse drug events were observed in any study. CONCLUSION: These studies demonstrated 0.5% w/v EPN administered topically at 1 mg/kg body weight to be highly efficacious against a broad range of ovine gastrointestinal nematodes and D. filaria lungworms and well tolerated by sheep of different ages, breeds, gender and physiological status.
Assuntos
Antinematódeos/uso terapêutico , Gastroenteropatias/veterinária , Ivermectina/análogos & derivados , Pneumopatias Parasitárias/veterinária , Infecções por Nematoides/veterinária , Doenças dos Ovinos/parasitologia , Animais , Antinematódeos/farmacocinética , Feminino , Gastroenteropatias/parasitologia , Helmintíase Animal/tratamento farmacológico , Ivermectina/farmacocinética , Ivermectina/uso terapêutico , Pneumopatias Parasitárias/tratamento farmacológico , Masculino , Infecções por Nematoides/tratamento farmacológico , Ovinos , Doenças dos Ovinos/tratamento farmacológicoRESUMO
Identifying individual genetic variation in drug metabolism pathways is of importance not only in livestock, but also in humans in order to provide the ultimate goal of giving the right drug at the right dose at the right time. Our objective was to identify individual genes and gene networks involved in metabolizing fenbendazole (FBZ) and flunixin meglumine (FLU) in swine liver. The population consisted of female and castrated male pigs that were sired by boars represented by 4 breeds. Progeny were randomly placed into groups: no drug (UNT), FLU or FBZ administered. Liver transcriptome profiles from 60 animals with extreme (i.e. fast or slow drug metabolism) pharmacokinetic (PK) profiles were generated from RNA sequencing. Multiple cytochrome P450 (CYP1A1, CYP2A19 and CYP2C36) genes displayed different transcript levels across treated versus UNT. Weighted gene co-expression network analysis identified 5 and 3 modules of genes correlated with PK parameters and a portion of these were enriched for biological processes relevant to drug metabolism for FBZ and FLU, respectively. Genes within identified modules were shown to have a higher transcript level relationship (i.e. connectivity) in treated versus UNT animals. Investigation into the identified genes would allow for greater insight into FBZ and FLU metabolism.
Assuntos
Antinematódeos/farmacocinética , Clonixina/análogos & derivados , Fenbendazol/farmacocinética , Expressão Gênica , Fígado/metabolismo , Sus scrofa/genética , Animais , Clonixina/farmacocinética , Feminino , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Redes Reguladoras de Genes , Fígado/efeitos dos fármacos , Masculino , TranscriptomaRESUMO
Mebendazole is approved for use in aquatic animals and is widely used in Chinese aquaculture. We developed a pharmacokinetic and residue analysis for mebendazole levels in the goldfish (Carassius auratus). Plasma and muscle samples of C. auratus were taken after oral administration of 10 mg/kg mebendazole. The maximal drug plasma concentration of 0.55 mg/L was achieved at 48 hr and then declined with the elimination half-life (T1/2ß ) of 7.99 hr. Administration of 10 mg/kg by oral gavage for 5 successive days resulted in a peak mebendazole concentration of 0.70 mg/kg in muscle at 96 hr after the last dose. The drug was then eliminated at a relatively slow rate from muscle with T1/2ß of 68.41 hr. There was no detectable mebendazole in any muscle samples at 24 days postadministration. The AUClast in plasma and muscle was 19.42 and 105.33 mg hr/L, respectively. These data provide information for dosage recommendations and withdrawal time determinations for mebendazole use in aquariums.
Assuntos
Antinematódeos/farmacocinética , Carpa Dourada/metabolismo , Mebendazol/farmacocinética , Administração Oral , Animais , Antinematódeos/administração & dosagem , Antinematódeos/análise , Antinematódeos/sangue , Carpa Dourada/sangue , Meia-Vida , Mebendazol/administração & dosagem , Mebendazol/análise , Mebendazol/sangue , Músculo Esquelético/químicaRESUMO
Phellinus baumii is a yellow mushroom long used in alternative medicine in Korea and other central Asian countries. To identify genes affected by a single or 7-day oral administration of a water extract of Ph. Baumii, mouse liver tissue was analyzed using microarrays. The results showed that 8 and 23 genes were upregulated and 3 and 11 genes downregulated more than 3-fold by single and multiple oral administrations of 100 mg/kg PBE, respectively. Among the upregulated genes, the expression of 3 flavin-containing monooxygenase (Fmo) family genes, Fmo2-4, was upregulated in a concentration-dependent manner. The microarray analysis also showed that single and multiple administrations of PBE increased Fmo3 expression in the mouse liver by 5.1- and 17.6-fold, respectively. To validate the Fmo expression microarray data, polymerase chain reaction was used to confirm the induction of Fmo subclass genes. Mice were orally administered Ph. Baumii extract (PBE), Ph. Baumii water, or Ph. Baumii ß-glucan fraction (PBG) for 7 days, and induction of the expression of the Fmo subclasses in the liver, lung, and kidney was investigated. Fmo2, Fmo3, and Fmo4 expression was induced by both PBE and PBG in the lung, liver, and kidney, respectively. However, no induction of Fmo1 and Fmo5 was detected. To investigate the metabolic acceleration of xenobiotic by PBE, carbendazim was orally administered to mice and its clearance from the blood analyzed. High-performance liquid chromatography analysis showed accelerated clearance of serum carbendazim by oral administration of PBE for 7 days, as evidenced by the reduced peak plasma concentration, time to reach the peak plasma concentration, and area under the curve values. Moreover, PBE increased the carbendazim clearance rate at the higher concentration. These data indicate that oral administration of PBE resulted in modulation of gene expression: PBE was responsible for the induction of Fmo2, Fmo3, and Fmo4 expression. PBE also accelerated the metabolic clearance of carbendazim in vivo and so could be applied to the detoxification of xenobiotics such as drugs, pesticides, and nicotine.
Assuntos
Agaricales/química , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Oxigenases/metabolismo , Administração Oral , Animais , Antinematódeos/metabolismo , Antinematódeos/farmacocinética , Benzimidazóis/metabolismo , Benzimidazóis/farmacocinética , Carbamatos/metabolismo , Carbamatos/farmacocinética , Masculino , Camundongos , Camundongos Endogâmicos ICR , Oxigenases/genética , Reação em Cadeia da Polimerase/métodos , Análise Serial de Proteínas , Reprodutibilidade dos TestesRESUMO
The purpose of this study was to evaluate the pharmacokinetics of moxidectin in alpacas after single subcutaneous injection of a non-aqueous formulation or oral administration of an aqueous drench at 0.2 mg∗kg(-1). Plasma moxidectin concentrations were measured with reverse phase HPLC, and data analyzed using non-compartmental methods. Half-life was longer (p=0.02) after subcutaneous administration than oral (292+/-170 vs 33+/-39 h). The area under the concentration-time curve was greater (p=0.04) following subcutaneous administration (1484.8+/-1049.5 h∗ng∗ml(-1)) than oral (157.6+/-85.9 h∗ng∗ml(-1)). The peak concentration (Cmax) was higher and the after subcutaneous administration, but the difference was not statistically significant (p=0.18). The relative bioavailability of the oral moxidectin to the subcutaneous moxidectin was 11%. The data suggest a higher relative bioavailability following subcutaneous compared to oral administration. Further studies are needed to determine the therapeutic concentrations of moxidectin in alpacas.
Assuntos
Antinematódeos/farmacocinética , Camelídeos Americanos , Hemoncose/veterinária , Haemonchus/efeitos dos fármacos , Macrolídeos/farmacocinética , Administração Oral , Animais , Antinematódeos/administração & dosagem , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão/veterinária , Hemoncose/tratamento farmacológico , Hemoncose/parasitologia , Meia-Vida , Injeções Subcutâneas/veterinária , Macrolídeos/administração & dosagem , MasculinoRESUMO
This study investigates 3 amorphous technologies to improve the dissolution rate and oral bioavailability of flubendazole (FLU). The selected approaches are (1) a standard spray-dried dispersion with hydroxypropylmethylcellulose (HPMC) E5 or polyvinylpyrrolidone-vinyl acetate 64, both with Vitamin E d-α-tocopheryl polyethylene glycol succinate; (2) a modified process spray-dried dispersion (MPSDD) with either HPMC E3 or hydroxypropylmethylcellulose acetate succinate (HPMCAS-M); and (3) confining FLU in ordered mesoporous silica (OMS). The physicochemical stability and in vitro release of optimized formulations were evaluated following 2 weeks of open conditions at 25°C/60% relative humidity (RH) and 40°C/75% RH. All formulations remained amorphous at 25°C/60% RH. Only the MPSDD formulation containing HPMCAS-M and 3/7 (wt./wt.) FLU/OMS did not crystallize following 40°C/75% RH exposure. The OMS and MPSDD formulations contained the lowest and highest amount of hydrolyzed degradant, respectively. All formulations were dosed to rats at 20 mg/kg in suspension. One FLU/OMS formulation was also dosed as a capsule blend. Plasma concentration profiles were determined following a single dose. In vivo findings show that the OMS capsule and suspension resulted in the overall highest area under the curve and Cmax values, respectively. These results cross-evaluate various amorphous formulations and provide a link to enhanced biopharmaceutical performance.
Assuntos
Antinematódeos/administração & dosagem , Antinematódeos/farmacocinética , Mebendazol/análogos & derivados , Animais , Dessecação , Composição de Medicamentos , Sistemas de Liberação de Medicamentos , Umidade , Masculino , Mebendazol/administração & dosagem , Mebendazol/farmacocinética , Metilcelulose/análogos & derivados , Mucosa Bucal/metabolismo , Povidona , Ratos , Ratos Sprague-Dawley , Suspensões , Vitamina E/químicaRESUMO
The objective of the present study was to estimate the distribution of the carbamate pesticide carfbofuran in the organism of the warm-blooded animals (rats) after its intragastric administration. It was shown that large amounts of unmetabolized carbofuran were present in the internal organs and biological fluids. The highest content of carbofuran was recorded in the stomach, large and small intestines, testicles, urinary bladder, ureters, and heart.